Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Clinical Trials: Overview01:11

Clinical Trials: Overview

4.7K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.7K
Preclinical Development: Overview01:28

Preclinical Development: Overview

4.8K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.8K
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

627
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
627
Drug Discovery: Overview01:26

Drug Discovery: Overview

10.3K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
10.3K
Production of Pharmaceuticals01:30

Production of Pharmaceuticals

90
Industrial insulin production uses genetically engineered E. coli expressing a proinsulin gene controlled by a tryptophan promoter and containing a methionine linker for later cleavage. The cells also carry ampicillin resistance for selective growth. Seed cultures are stored at −80 °C and production begins by thawing a small amount to inoculate starter cultures, which are progressively scaled to a 50,000-L bioreactor. In the bioreactor, E. coli grow in nutrient-rich media under...
90
Drug Product Performance: In Vitro–In Vivo Correlation01:20

Drug Product Performance: In Vitro–In Vivo Correlation

430
In pharmaceutical development, it's crucial to establish a predictive in vitro–in vivo correlation (IVIVC) for two or more formulations to gain a comprehensive understanding of release properties. IVIVC reduces the need for costly in vivo studies and facilitates the establishment of meaningful dissolution specifications with significant cost savings and decreased regulatory burden. Furthermore, a meaningful IVIVC should predict Cmax and AUC within 20%, aligning with FDA guidance while...
430

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

High-security probabilistic shaping method via chaotic tagging.

Optics letters·2026
Same author

Integrating digital PCR and metagenomics to quantify potential soilborne bacterial pathogens in urban ecosystem.

Journal of hazardous materials·2026
Same author

Diversity and geographic distribution of antibiotic resistance in food waste anaerobic digestion systems.

Journal of hazardous materials·2026
Same author

Advancements of nanoparticle-based adhesive materials.

Materials horizons·2026
Same author

Phylogenetic assembly of methanogenesis regulates methane yield in food-waste anaerobic digestion.

The ISME journal·2026
Same author

Trends in Venture Capital Investment in AI-Driven Biopharmaceutical Startups.

Journal of medical Internet research·2026

Related Experiment Video

Updated: Apr 30, 2026

Hydrogel Arrays Enable Increased Throughput for Screening Effects of Matrix Components and Therapeutics in 3D Tumor Models
10:49

Hydrogel Arrays Enable Increased Throughput for Screening Effects of Matrix Components and Therapeutics in 3D Tumor Models

Published on: June 16, 2022

2.3K

Success Rates of Venture Capital Investment in Biopharmaceutical Development.

So-Yeon Kang1,2, Mingqian Liu1, Sean S Huang1

  • 1Department of Health Management and Policy, Georgetown University School of Health, Washington, DC.

Medical Care
|April 28, 2026
PubMed
Summary

Venture capital (VC)-backed startups show drug development success rates comparable to large manufacturers. Factors like drug type and investment size significantly influence clinical trial progression and FDA approval.

Keywords:
US Food and Drug Administration Approvalbiopharmaceutical innovationdrug developmentresearch and development financingventure capital

More Related Videos

Process Optimization using High Throughput Automated Micro-Bioreactors in Chinese Hamster Ovary Cell Cultivation
09:28

Process Optimization using High Throughput Automated Micro-Bioreactors in Chinese Hamster Ovary Cell Cultivation

Published on: May 18, 2020

8.0K
A High-throughput Automated Platform for the Development of Manufacturing Cell Lines for Protein Therapeutics
07:48

A High-throughput Automated Platform for the Development of Manufacturing Cell Lines for Protein Therapeutics

Published on: September 22, 2011

23.8K

Related Experiment Videos

Last Updated: Apr 30, 2026

Hydrogel Arrays Enable Increased Throughput for Screening Effects of Matrix Components and Therapeutics in 3D Tumor Models
10:49

Hydrogel Arrays Enable Increased Throughput for Screening Effects of Matrix Components and Therapeutics in 3D Tumor Models

Published on: June 16, 2022

2.3K
Process Optimization using High Throughput Automated Micro-Bioreactors in Chinese Hamster Ovary Cell Cultivation
09:28

Process Optimization using High Throughput Automated Micro-Bioreactors in Chinese Hamster Ovary Cell Cultivation

Published on: May 18, 2020

8.0K
A High-throughput Automated Platform for the Development of Manufacturing Cell Lines for Protein Therapeutics
07:48

A High-throughput Automated Platform for the Development of Manufacturing Cell Lines for Protein Therapeutics

Published on: September 22, 2011

23.8K

Area of Science:

  • Biopharmaceutical Research
  • Drug Development
  • Venture Capital Funding

Background:

  • Biopharmaceutical companies increasingly rely on venture capital (VC)-funded startups for early-stage research and development (R&D).
  • The effectiveness of VC funding in bringing new drugs to market remains largely unexamined.

Purpose of the Study:

  • To evaluate the clinical trial outcomes of VC-backed biopharmaceutical startups.
  • To identify key factors influencing the progression of these trials.

Main Methods:

  • A retrospective cohort study analyzed VC-backed biopharmaceutical clinical trials.
  • Phase 1 trials initiated between 2006 and 2015 were tracked until April 2024.
  • Progression to subsequent phases and FDA approval was assessed using multinomial logistic regression.

Main Results:

  • Of 1357 VC-backed phase 1 trials, 14.1% achieved FDA approval.
  • Cancer trials had an 8.7% FDA approval rate.
  • Biological drugs were less likely to reach phase 3 or gain FDA approval compared to small molecules.
  • Higher initial investment correlated with increased trial progression and FDA approval.

Conclusions:

  • VC-backed startups demonstrate clinical trial success rates similar to established large manufacturers.
  • Drug modality, therapeutic area, and investment size are critical determinants of R&D success.
  • Strategic capital allocation and development planning are crucial for optimizing outcomes.